Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that severe or moderate COVID-19 altered sex hormone and cortisol levels in lung tissues of patients with non-small cell lung cancer, particularly in women, suggesting potential implications for lung cancer progression and treatment outcomes.

This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.

This case report suggests that topical St. John's wort oil may cause severe skin toxicity during radiotherapy for non-small cell lung cancer, acting as a significant radiosensitizer.

This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.

This study describes a case of erlotinib-induced alopecia, unresponsive to traditional corticosteroid treatments, that was successfully managed with doxycycline, suggesting a novel approach for EGFR inhibitor-associated alopecia.

This review reports that KRT80 is overexpressed in various cancers, enhancing cancer cell proliferation, invasiveness, and migration, suggesting it as a potential therapeutic target, though more clinical studies are needed to fully understand its role in cancer prognosis.

In this study, chemotherapy and radiotherapy were observed to normalize blood cell counts and improve quality of life in lung cancer patients, though some variations and localized side effects occurred.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

This source concludes that repurposing existing drugs, such as using metformin with other treatments in advanced non-small cell lung cancer, may enhance cancer patient outcomes, although various technical and legal challenges need addressing.

This study found that co-administering sasam-Kyeongokgo with gefitinib enhanced gefitinib's anti-tumor activity and exhibited favorable anti-cachexia effects in mice with non-small-cell lung cancer.

This case report details a 54-year-old woman with metastatic non-small-cell lung cancer who experienced severe hair loss and exanthematous drug eruption, potentially linked to erlotinib hypersensitivity.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.

In this review, the researchers identify and discuss promising molecular and genetic targets for lung cancer therapy, suggesting that advancements in understanding these targets could lead to new drug developments and more effective treatments.

This case report describes how discontinuing the EGFR inhibitor gefitinib led to rapid improvement of erosive scalp pustules in a woman with non-small-cell lung cancer, despite previous antibiotic and steroid treatment failures.

This paper reviews research on the link between small cell lung cancer and metabolic syndrome, highlighting that existing studies indicate metabolic syndrome may contribute to lung cancer development through mechanisms like insulin resistance, chronic inflammation, and oxidative stress.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

This case report describes the first known instance of hair and eyebrow hyperpigmentation in a patient after seven months of gefitinib treatment for non-small cell lung cancer.

This study reports two cases of PRIDE complex in nonsmall cell lung cancer patients treated with erlotinib and gefitinib, highlighting cutaneous reactions like papulopustules and paronychia.

In this study, in vitro and in vivo models showed that chrysin enhanced the efficacy of docetaxel and reduced its adverse effects in non–small cell lung cancer treatment.

In this study, AS101 combined with chemotherapy significantly reduced the severity of chemotherapy-induced alopecia in non-small-cell-lung-cancer patients and may involve immune mechanisms related to IL-1 and PGE2.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This case study highlights the importance of early diagnosis and treatment of acneiform eruptions associated with erlotinib in a 67-year-old male patient with non-small cell lung cancer to ensure patient compliance.

This study found that Brigatinib-loaded nanospanlastics demonstrated enhanced cytotoxicity against lung cancer cells and improved drug stability and release compared to free Brigatinib.

This case report documents new hair growth in a 57-year-old man with androgenic alopecia after receiving gefitinib treatment for non-small-cell lung cancer.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

This study concludes that combining chemotherapy with immune checkpoint inhibitors is additive rather than synergistic in terms of adverse events for advanced non-small cell lung cancer patients.